Deterministic preview of biotech M&A deal-signal candidates — Phase 2/3 trial counts and the industry-sponsored asset list straight off ClinicalTrials.gov, no LLM synthesis. For agents with small per-call budgets; upgrade to deal-signal for acquisition rationale, deal comps with dollar values, likely acquirers and timing signals.
| Network | Scheme | Amount | Pay To |
|---|---|---|---|
| Base | exact | $0.25 USDC | 0x50ab...12fc |
| Base | exact | $0.25 USDC | 0x50ab...12fc |
| solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp | exact | 0.25 tokens | 985iFj...5KX1 |
| Polygon | exact | $0.25 USDC | 0x50ab...12fc |
| Arbitrum One | exact | $0.25 USDC | 0x50ab...12fc |
| eip155:480 | exact | 0.25 tokens | 0x50ab...12fc |
| eip155:143 | exact | 0.25 tokens | 0x50ab...12fc |
| eip155:196 | exact | 0.25 tokens | 0x50ab...12fc |
| eip155:999 | exact | 0.25 tokens | 0x50ab...12fc |
| algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k | exact | 0.25 tokens | 62A253...GI7I |
| xrpl:0 | exact | 0.25 tokens | rMnHeu...Eh32 |
| xrpl:0 | exact | 0.25 | rMnHeu...Eh32 |
| eip155:56 | exact | 0.250000 tokens | 0x50ab...12fc |